A novel study evaluation strategy in the systematic review of animal toxicology studies for human health assessments of environmental chemicals.


Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
08 2020
Historique:
received: 23 09 2019
revised: 09 04 2020
accepted: 10 04 2020
pubmed: 21 5 2020
medline: 15 12 2020
entrez: 21 5 2020
Statut: ppublish

Résumé

A key aspect of the systematic review process is study evaluation to understand the strengths and weaknesses of individual studies included in the review. The present manuscript describes the process currently being used by the Environmental Protection Agency's (EPA) Integrated Risk Information System (IRIS) Program to evaluate animal toxicity studies, illustrated by application to the recent systematic reviews of two phthalates: diisobutyl phthalate (DIBP) and diethyl phthalate (DEP). The IRIS Program uses a domain-based approach that was developed after careful consideration of tools used by others to evaluate experimental animal studies in toxicology and pre-clinical research. Standard practice is to have studies evaluated by at least two independent reviewers for aspects related to reporting quality, risk of bias/internal validity (e.g., randomization, blinding at outcome assessment, methods used to expose animals and assess outcomes, etc.), and sensitivity to identify factors that may limit the ability of a study to detect a true effect. To promote consistency across raters, prompting considerations and example responses are provided to reviewers, and a pilot phase is conducted. The evaluation process is performed separately for each outcome reported in a study, as the utility of a study may vary for different outcomes. Input from subject matter experts is used to identify chemical- and outcome-specific considerations (e.g., lifestage of exposure and outcome assessment when considering reproductive effects) to guide judgments within particular evaluation domains. For each evaluation domain, reviewers reach a consensus on a rating of Good, Adequate, Deficient, or Critically Deficient. These individual domain ratings are then used to determine the overall confidence in the study (High Confidence, Medium Confidence, Low Confidence, or Deficient). Study evaluation results, including the justifications for reviewer judgements, are documented and made publicly available in EPA's version of Health Assessment Workspace Collaborative (HAWC), a free and open source web-based software application. (The views expressed are those of the authors and do not necessarily represent the views or policies of the US EPA).

Identifiants

pubmed: 32434117
pii: S0160-4120(19)33533-0
doi: 10.1016/j.envint.2020.105736
pmc: PMC8422842
mid: NIHMS1733822
pii:
doi:

Substances chimiques

Environmental Pollutants 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105736

Subventions

Organisme : Intramural EPA
ID : EPA999999
Pays : United States

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Stroke. 2004 May;35(5):1203-8
pubmed: 15060322
Toxicol Pathol. 2004 Jul-Aug;32(4):448-66
pubmed: 15204968
Regul Toxicol Pharmacol. 2003 Jun;37(3):356-69
pubmed: 12758216
Environ Int. 2016 Jul-Aug;92-93:605-10
pubmed: 27156196
Toxicol Lett. 2019 Sep 15;312:167-172
pubmed: 31100492
Toxicol Lett. 2013 Dec 16;223(3):315-21
pubmed: 23542816
Environ Int. 2019 Apr;125:579-594
pubmed: 30591249
Toxicol Sci. 2016 Jan;149(1):178-91
pubmed: 26454885
Microbiome. 2016 Jun 14;4(1):26
pubmed: 27301250
Endocrinology. 2008 Oct;149(10):5280-7
pubmed: 18566125
Toxicology. 2018 Feb 15;395:23-33
pubmed: 29325824
Environ Int. 2016 Jul-Aug;92-93:716-28
pubmed: 27156197
Endocrinology. 2006 Nov;147(11):5352-62
pubmed: 16916955
Crit Rev Toxicol. 2000 Mar;30(2):197-252
pubmed: 10759431
Toxicol Lett. 2000 Jan 5;111(3):271-8
pubmed: 10643872
Environ Toxicol Pharmacol. 2006 Jan;21(1):93-102
pubmed: 21783644
Reprod Toxicol. 2019 Jun 28;:
pubmed: 31260805
Toxicol Pathol. 2004 Jan-Feb;32(1):126-31
pubmed: 14713558
Regul Toxicol Pharmacol. 2006 Jul;45(2):169-77
pubmed: 16750591
Exp Anim. 2001 Apr;50(2):173-7
pubmed: 11381622
Endocrinology. 2010 Jun;151(6):2868-75
pubmed: 20392824
Philos Trans R Soc Lond B Biol Sci. 2010 May 27;365(1546):1697-712
pubmed: 20403879
Environ Toxicol Pharmacol. 2007 May;23(3):319-27
pubmed: 21783775
Okajimas Folia Anat Jpn. 2010 Feb;86(4):129-36
pubmed: 20560449
Toxicology. 2000 May 19;147(1):23-31
pubmed: 10837929
Environ Int. 2016 Jul-Aug;92-93:630-46
pubmed: 27039952
J Appl Toxicol. 2018 Dec;38(12):1460-1470
pubmed: 29806706
Environ Health Perspect. 2016 Jan;124(1):39-45
pubmed: 26047088
Environ Health Perspect. 2013 Sep;121(9):985-92
pubmed: 23771496
PLoS One. 2014 Jun 06;9(6):e98856
pubmed: 24906117
Reprod Toxicol. 2015 Jul;54:110-9
pubmed: 25554385
Toxicol Sci. 2001 Jun;61(2):201-10
pubmed: 11353128
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Ecotoxicol Environ Saf. 2007 Sep;68(1):118-25
pubmed: 16814384
Environ Health Perspect. 2014 Oct;122(10):1015-27
pubmed: 24968374
Toxicol Pathol. 2001 Jan-Feb;29(1):49-63
pubmed: 11215684
BMC Med Res Methodol. 2014 Mar 26;14:43
pubmed: 24667063
Hum Reprod Update. 2014 Mar-Apr;20(2):231-49
pubmed: 24077978
Endocr Rev. 2009 Dec;30(7):883-925
pubmed: 19887492

Auteurs

Laura Dishaw (L)

US EPA, Center for Public Health and Environmental Assessment, Research Triangle Park, NC, United States. Electronic address: Dishaw.Laura@epa.gov.

Erin Yost (E)

US EPA, Center for Public Health and Environmental Assessment, Research Triangle Park, NC, United States.

Xabier Arzuaga (X)

US EPA, Center for Public Health and Environmental Assessment, Washington, DC, United States.

April Luke (A)

US EPA, Office of Emergency Management, Washington, DC, United States.

Andrew Kraft (A)

US EPA, Center for Public Health and Environmental Assessment, Washington, DC, United States.

Teneille Walker (T)

US EPA, Center for Public Health and Environmental Assessment, Washington, DC, United States.

Kris Thayer (K)

US EPA, Center for Public Health and Environmental Assessment, Research Triangle Park, NC, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH